PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

NCT03650348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Bladder Cancer
HER2-positive Solid Tumor

Interventions

DRUG: PRS-343 in Combination with Atezolizumab

Sponsor

Pieris Pharmaceuticals, Inc.